Chronic Myelogenous Leukemia, Version 1.2015

Restricted access

Chronic myelogenous leukemia (CML) is usually diagnosed in the chronic phase. Untreated chronic phase CML will eventually progress to advanced phase (accelerated or blast phase) CML. Tyrosine kinase inhibitors (TKIs) have been shown to induce favorable response rates in patients with accelerated and blast phase CML. The addition of TKIs to chemotherapy has also been associated with improved outcomes in patients with blast phase CML. Allogeneic hematopoietic stem cell transplant remains a potentially curative option for patients with advanced phase CML, although treatment with a course of TKIs will be beneficial as a bridge to transplant. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with advanced phase CML.

  • 1.

    Howlader N, Noone AM, eds. SEER Cancer Statistics Review, 1975-2008, National Cancer Institute. Bethesda, MD, www.seer.cancer.gov/csr/1975_2008/, based on November 2010 SEER data submission, posted to the SEER website, 2011.

    • Search Google Scholar
    • Export Citation
  • 2.

    Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014;64:929.

  • 3.

    Faderl S, Talpaz M, Estrov Z. The biology of chronic myeloid leukemia. N Engl J Med 1999;341:164172.

  • 4.

    Verma D, Kantarjian HM, Jones D. Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance. Blood 2009;114:22322235.

    • Search Google Scholar
    • Export Citation
  • 5.

    Sawyers CL. Chronic myeloid leukemia. N Engl J Med 1999;340:13301340.

  • 6.

    Radich JP, Dai H, Mao M. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci U S A 2006;103:27942799.

    • Search Google Scholar
    • Export Citation
  • 7.

    Jamieson CHM, Ailles LE, Dylla SJ. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med 2004;351:657667.

    • Search Google Scholar
    • Export Citation
  • 8.

    Kantarjian HM, Deisseroth A, Kurzrock R. Chronic myelogenous leukemia: a concise update. Blood 1993;82:691703.

  • 9.

    Savage DG, Szydlo RM, Chase A. Bone marrow transplantation for chronic myeloid leukaemia: the effects of differing criteria for defining chronic phase on probabilities of survival and relapse. Br J Haematol 1997;99:3035.

    • Search Google Scholar
    • Export Citation
  • 10.

    Sokal JE, Baccarani M, Russo D, Tura S. Staging and prognosis in chronic myelogenous leukemia. Semin Hematol 1988;25:4961.

  • 11.

    Talpaz M, Silver RT, Druker BJ. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002;99:19281937.

    • Search Google Scholar
    • Export Citation
  • 12.

    Cortes JE, Talpaz M, O’Brien S. Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the World Health Organization proposal. Cancer 2006;106:13061315.

    • Search Google Scholar
    • Export Citation
  • 13.

    Swerdlow SH, Campo E, Harris NL. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th edition. Lyon, France: IARC; 2008.

  • 14.

    Druker BJ. Chronic Myelogenous Leukemia. In: DeVita VT Jr, Lawrence TS, Rosenburg SA, eds. DeVita, Hellman, and Rosenberg’s Cancer: Principles and Practice of Oncology. Vol. 2. 8th edition. Philadelphia, PA: Lippincott Williams & Wilkins; 2007:22672304.

    • Search Google Scholar
    • Export Citation
  • 15.

    Guo JQ, Wang JY, Arlinghaus RB. Detection of BCR-ABL proteins in blood cells of benign phase chronic myelogenous leukemia patients. Cancer Res 1991;51:30483051.

    • Search Google Scholar
    • Export Citation
  • 16.

    Biernaux C, Loos M, Sels A. Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals. Blood 1995;86:31183122.

    • Search Google Scholar
    • Export Citation
  • 17.

    Bose S, Deininger M, Gora-Tybor J. The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease. Blood 1998;92:33623367.

    • Search Google Scholar
    • Export Citation
  • 18.

    Sokal J, Cox E, Baccarani M. Prognostic discrimination in “good-risk” chronic granulocytic leukemia. Blood 1984;63:789799.

  • 19.

    Hasford J, Pfirrmann M, Hehlmann R. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst 1998;90:850858.

    • Search Google Scholar
    • Export Citation
  • 20.

    Cortes JE, Talpaz M, Beran M. Philadelphia chromosome-negative chronic myelogenous leukemia with rearrangement of the breakpoint cluster region. Long-term follow-up results. Cancer 1995;75:464470.

    • Search Google Scholar
    • Export Citation
  • 21.

    Ernst T, Chase AJ, Score J. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet 2010;42:722726.

    • Search Google Scholar
    • Export Citation
  • 22.

    Kohlmann A, Grossmann V, Klein HU. Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1. J Clin Oncol 2010;28:38583865.

    • Search Google Scholar
    • Export Citation
  • 23.

    Oh ST, Simonds EF, Jones C. Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. Blood 2010;116:988992.

    • Search Google Scholar
    • Export Citation
  • 24.

    Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia 2010;24:11281138.

    • Search Google Scholar
    • Export Citation
  • 25.

    Mascarenhas J, Roper N, Chaurasia P, Hoffman R. Epigenetic abnormalities in myeloproliferative neoplasms: a target for novel therapeutic strategies. Clin Epigenetics 2011;2:197212.

    • Search Google Scholar
    • Export Citation
  • 26.

    Stegelmann F, Bullinger L, Schlenk RF. DNMT3A mutations in myeloproliferative neoplasms. Leukemia 2011;25:12171219.

  • 27.

    Klampfl T, Gisslinger H, Harutyunyan AS. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 2013;369:23792390.

  • 28.

    Maxson JE, Gotlib J, Pollyea DA. Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML. N Engl J Med 2013;368:17811790.

    • Search Google Scholar
    • Export Citation
  • 29.

    Meggendorfer M, Bacher U, Alpermann T. SETBP1 mutations occur in 9% of MDS/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations. Leukemia 2013;27:18521860.

    • Search Google Scholar
    • Export Citation
  • 30.

    Cross NC, Reiter A. Fibroblast growth factor receptor and platelet-derived growth factor receptor abnormalities in eosinophilic myeloproliferative disorders. Acta Haematol 2008;119:199206.

    • Search Google Scholar
    • Export Citation
  • 31.

    Kantarjian HM, Cortes J, O’Brien S. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood 2002;99:35473553.

    • Search Google Scholar
    • Export Citation
  • 32.

    Kantarjian HM, O’Brien S, Cortes JE. Treatment of Philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate. Clin Cancer Res 2002;8:21672176.

    • Search Google Scholar
    • Export Citation
  • 33.

    Sawyers CL, Hochhaus A, Feldman E. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002;99:35303539.

    • Search Google Scholar
    • Export Citation
  • 34.

    Palandri F, Castagnetti F, Testoni N. Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up. Haematologica 2008;93:17921796.

    • Search Google Scholar
    • Export Citation
  • 35.

    Palandri F, Castagnetti F, Alimena G. The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up. Haematologica 2009;94:205212.

    • Search Google Scholar
    • Export Citation
  • 36.

    Silver RT, Cortes J, Waltzman R. Sustained durability of responses and improved progression-free and overall survival with imatinib treatment for accelerated phase and blast crisis chronic myeloid leukemia: long-term follow-up of the STI571 0102 and 0109 trials. Haematologica 2009;94:743744.

    • Search Google Scholar
    • Export Citation
  • 37.

    Rea D, Etienne G, Nicolini F. First-line imatinib mesylate in patients with newly diagnosed accelerated phase-chronic myeloid leukemia. Leukemia 2012;26:22542259.

    • Search Google Scholar
    • Export Citation
  • 38.

    Ohanian M, Kantarjian HM, Quintas-Cardama A. Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phase. Clin Lymphoma Myeloma Leuk 2014;14:155-162 e151.

    • Search Google Scholar
    • Export Citation
  • 39.

    Cortes J, Kim DW, Raffoux E. Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase. Leukemia 2008;22:21762183.

    • Search Google Scholar
    • Export Citation
  • 40.

    Apperley JF, Cortes JE, Kim DW. Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START A trial. J Clin Oncol 2009;27:34723479.

    • Search Google Scholar
    • Export Citation
  • 41.

    Kantarjian H, Cortes J, Kim DW. Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up. Blood 2009;113:63226329.

    • Search Google Scholar
    • Export Citation
  • 42.

    le Coutre PD, Giles FJ, Hochhaus A. Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results. Leukemia 2012;26:11891194.

    • Search Google Scholar
    • Export Citation
  • 43.

    Giles FJ, Kantarjian HM, le Coutre PD. Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase. Leukemia 2012;26:959962.

    • Search Google Scholar
    • Export Citation
  • 44.

    Gambacorti-Passerini C, Cortes JE, Khoury HJ. Safety and efficacy of bosutinib in patients with AP and BP CML and ph+ ALL following resistance/intolerance to imatinib and other TKIs: Update from study SKI-200 [abstract]. J Clin Oncol 2010;28(Suppl):Abstract 6509.

    • Search Google Scholar
    • Export Citation
  • 45.

    Cortes JE, Kim DW, Pinilla-Ibarz J. A Phase 2 Trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med 2013;369:17831796.

    • Search Google Scholar
    • Export Citation
  • 46.

    Kantarjian HM, Kim DW, Pinilla-Ibarz J. Ponatinib (PON) in patients (pts) with Philadelphia chromosome-positive (Ph+) leukemias resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation: longer-term follow up of the PACE trial [abstract]. J Clin Oncol 2014;32(Suppl):Abstract 7081.

    • Search Google Scholar
    • Export Citation
  • 47.

    Guilhot F, Apperley J, Kim DW. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood 2007;109:41434150.

    • Search Google Scholar
    • Export Citation
  • 48.

    Cortes J, Rousselot P, Kim DW. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood 2007;109:32073213.

    • Search Google Scholar
    • Export Citation
  • 49.

    Saglio G, Hochhaus A, Goh YT. Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily. Cancer 2010;116:38523861.

    • Search Google Scholar
    • Export Citation
  • 50.

    le Coutre P, Ottmann OG, Giles F. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood 2008;111:18341839.

    • Search Google Scholar
    • Export Citation
  • 51.

    Efficace F, Baccarani M, Breccia M. Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib. Leukemia 2013;27:15111519.

    • Search Google Scholar
    • Export Citation
  • 52.

    Berman E, Nicolaides M, Maki RG. Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med 2006;354:20062013.

    • Search Google Scholar
    • Export Citation
  • 53.

    Berman E, Girotra M, Cheng C. Effect of long term imatinib on bone in adults with chronic myelogenous leukemia and gastrointestinal stromal tumors. Leuk Res 2013;37:790794.

    • Search Google Scholar
    • Export Citation
  • 54.

    Quintas-Cardama A, Kantarjian H, O’Brien S. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol 2007;25:39083914.

    • Search Google Scholar
    • Export Citation
  • 55.

    Porkka K, Khoury HJ, Paquette RL. Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion. Cancer 2010;116:377386.

    • Search Google Scholar
    • Export Citation
  • 56.

    Mattei D, Feola M, Orzan F. Reversible dasatinib-induced pulmonary arterial hypertension and right ventricle failure in a previously allografted CML patient. Bone Marrow Transplant 2009;43:967968.

    • Search Google Scholar
    • Export Citation
  • 57.

    Rasheed W, Flaim B, Seymour JF. Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia. Leuk Res 2009;33:861864.

    • Search Google Scholar
    • Export Citation
  • 58.

    Dumitrescu D, Seck C, ten Freyhaus H. Fully reversible pulmonary arterial hypertension associated with dasatinib treatment for chronic myeloid leukaemia. Eur Respir J 2011;38:218220.

    • Search Google Scholar
    • Export Citation
  • 59.

    Hennigs JK, Keller G, Baumann HJ. Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension? BMC Pulm Med 2011;11:30.

    • Search Google Scholar
    • Export Citation
  • 60.

    Montani D, Bergot E, Gunther S. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation 2012;125:21282137.

  • 61.

    Orlandi EM, Rocca B, Pazzano AS, Ghio S. Reversible pulmonary arterial hypertension likely related to long-term, low-dose dasatinib treatment for chronic myeloid leukaemia. Leuk Res 2012;36:e46.

    • Search Google Scholar
    • Export Citation
  • 62.

    Aichberger KJ, Herndlhofer S, Schernthaner GH. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Am J Hematol 2011;86:533539.

    • Search Google Scholar
    • Export Citation
  • 63.

    Tefferi A, Letendre L. Nilotinib treatment-associated peripheral artery disease and sudden death: yet another reason to stick to imatinib as front-line therapy for chronic myelogenous leukemia. Am J Hematol 2011;86:610611.

    • Search Google Scholar
    • Export Citation
  • 64.

    Giles FJ, Mauro MJ, Hong F. Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis. Leukemia 2013;27:13101315.

    • Search Google Scholar
    • Export Citation
  • 65.

    FDA Drug Safety Communication: FDA asks manufacturer of the leukemia drug Iclusig (ponatinib) to suspend marketing and sales. U.S. Food and Drug Administration Web site. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm373040.htm; 2013. Accessed October 21, 2014.

    • Search Google Scholar
    • Export Citation
  • 66.

    Ponatinib [package insert]. Cambridge, MA: ARIAD Pharmaceuticals, Inc.; 2014.

  • 67.

    Ali R, Ozkalemkas F, Kimya Y. Imatinib use during pregnancy and breast feeding: a case report and review of the literature. Arch Gynecol Obstet 2009;280:169175.

    • Search Google Scholar
    • Export Citation
  • 68.

    AlKindi S, Dennison D, Pathare A. Imatinib in pregnancy. Eur J Haematol 2005;74:535537.

  • 69.

    Ault P, Kantarjian H, O’Brien S. Pregnancy among patients with chronic myeloid leukemia treated with imatinib. J Clin Oncol 2006;24:12041208.

    • Search Google Scholar
    • Export Citation
  • 70.

    Choudhary DR, Mishra P, Kumar R. Pregnancy on imatinib: fatal outcome with meningocele. Ann Oncol 2006;17:178179.

  • 71.

    Heartin E, Walkinshaw S, Clark RE. Successful outcome of pregnancy in chronic myeloid leukaemia treated with imatinib. Leuk Lymphoma 2004;45:13071308.

    • Search Google Scholar
    • Export Citation
  • 72.

    Prabhash K, Sastry PS, Biswas G. Pregnancy outcome of two patients treated with imatinib. Ann Oncol 2005;16:19831984.

  • 73.

    Pye SM, Cortes J, Ault P. The effects of imatinib on pregnancy outcome. Blood 2008;111:55055508.

  • 74.

    Ramasamy K, Hayden J, Lim Z. Successful pregnancies involving men with chronic myeloid leukaemia on imatinib therapy. Br J Haematol 2007;137:374375.

    • Search Google Scholar
    • Export Citation
  • 75.

    Cortes J, O’Brien S, Ault P. Pregnancy outcomes among patients with chronic myeloid leukemia treated with dasatinib [abstract]. Blood 2008;112:Abstract 3230.

    • Search Google Scholar
    • Export Citation
  • 76.

    Conchon M, Sanabani SS, Serpa M. Successful pregnancy and delivery in a patient with chronic myeloid leukemia while on dasatinib therapy. Adv Hematol 2010;2010:136252136252.

    • Search Google Scholar
    • Export Citation
  • 77.

    Oweini H, Otrock ZK, Mahfouz RA, Bazarbachi A. Successful pregnancy involving a man with chronic myeloid leukemia on dasatinib. Arch Gynecol Obstet 2011;283:133134.

    • Search Google Scholar
    • Export Citation
  • 78.

    Conchon M, Sanabani SS, Bendit I. Two successful pregnancies in a woman with chronic myeloid leukemia exposed to nilotinib during the first trimester of her second pregnancy: case study. J Hematol Oncol 2009;2:4242.

    • Search Google Scholar
    • Export Citation
  • 79.

    Kantarjian HM, Talpaz M, Kontoyiannis D. Treatment of chronic myelogenous leukemia in accelerated and blastic phases with daunorubicin, high-dose cytarabine, and granulocyte-macrophage colony-stimulating factor. J Clin Oncol 1992;10:398405.

    • Search Google Scholar
    • Export Citation
  • 80.

    Derderian PM, Kantarjian HM, Talpaz M. Chronic myelogenous leukemia in the lymphoid blastic phase: characteristics, treatment response, and prognosis. Am J Med 1993;94:6974.

    • Search Google Scholar
    • Export Citation
  • 81.

    Dann EJ, Anastasi J, Larson RA. High-dose cladribine therapy for chronic myelogenous leukemia in the accelerated or blast phase. J Clin Oncol 1998;16:14981504.

    • Search Google Scholar
    • Export Citation
  • 82.

    Sacchi S, Kantarjian HM, O’Brien S. Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients. Cancer 1999;86:26322641.

    • Search Google Scholar
    • Export Citation
  • 83.

    Axdorph U, Stenke L, Grimfors G. Intensive chemotherapy in patients with chronic myelogenous leukaemia (CML) in accelerated or blastic phase--a report from the Swedish CML Group. Br J Haematol 2002;118:10481054.

    • Search Google Scholar
    • Export Citation
  • 84.

    Thomas DA, Faderl S, Cortes J. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood 2004;103:43964407.

    • Search Google Scholar
    • Export Citation
  • 85.

    Yanada M, Takeuchi J, Sugiura I. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group. J Clin Oncol 2006;24:460466.

    • Search Google Scholar
    • Export Citation
  • 86.

    de Labarthe A, Rousselot P, Huguet-Rigal F. Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study. Blood 2007;109:14081413.

    • Search Google Scholar
    • Export Citation
  • 87.

    Oki Y, Kantarjian HM, Gharibyan V. Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia. Cancer 2007;109:899906.

    • Search Google Scholar
    • Export Citation
  • 88.

    Quintas-Cardama A, Kantarjian H, Garcia-Manero G. A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase. Leuk Lymphoma 2007;48:283289.

    • Search Google Scholar
    • Export Citation
  • 89.

    Fruehauf S, Topaly J, Buss EC. Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis. Cancer 2007;109:15431549.

    • Search Google Scholar
    • Export Citation
  • 90.

    Thomas DA, O’Brien SM, Faderl S. Long-term outcome after hyper-CVAD and imatinib (IM) for de novo or minimally treated Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph-ALL) [abstract]. J Clin Oncol 2010;28(Suppl):Abstract 6506.

    • Search Google Scholar
    • Export Citation
  • 91.

    Deau B, Nicolini FE, Guilhot J. The addition of daunorubicin to imatinib mesylate in combination with cytarabine improves the response rate and the survival of patients with myeloid blast crisis chronic myelogenous leukemia (AFR01 study). Leuk Res 2011;35:777782.

    • Search Google Scholar
    • Export Citation
  • 92.

    Jabbour E, Kantarjian HM, Thomas DA. Phase II study of combination of hyperCVAD with ponatinib in frontline therapy of patients (pts) with Philadelphia chromosome (Ph) positive acute lymphoblastic leukemia (ALL) [abstract]. J Clin Oncol 2013;31(Suppl):Abstract 7024.

    • Search Google Scholar
    • Export Citation
  • 93.

    Benjamini O, Dumlao TL, Kantarjian H. Phase II trial of hyper CVAD and dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia. Am J Hematol 2014;89:282287.

    • Search Google Scholar
    • Export Citation
  • 94.

    Strati P, Kantarjian H, Thomas D. HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia. Cancer 2014;120:373380.

    • Search Google Scholar
    • Export Citation
  • 95.

    Nicolini FE, Khoury HJ, Akard L. Omacetaxine mepesuccinate for patients with accelerated phase chronic myeloid leukemia with resistance or intolerance to two or more tyrosine kinase inhibitors. Haematologica 2013;98:e7879.

    • Search Google Scholar
    • Export Citation
  • 96.

    Khoury HJ, Cortes J, Baccarani M. Omacetaxine mepesuccinate in patients with advanced chronic myeloid leukemia with resistance or intolerance to tyrosine kinase inhibitors [published online ahead of print April 28, 2014]. Leuk Lymphoma.

    • Search Google Scholar
    • Export Citation
  • 97.

    Fava C, Kantarjian HM, Jabbour E. Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase. Blood 2009;113:50585063.

    • Search Google Scholar
    • Export Citation
  • 98.

    Branford S, Melo JV, Hughes TP. Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter? Blood 2009;114:54265435.

    • Search Google Scholar
    • Export Citation
  • 99.

    Jabbour E, Branford S, Saglio G. Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia. Cancer 2011;117:18001811.

    • Search Google Scholar
    • Export Citation
  • 100.

    Soverini S, Hochhaus A, Nicolini FE. BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood 2011;118:12081215.

    • Search Google Scholar
    • Export Citation
  • 101.

    Muller MC, Cortes JE, Kim DW. Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations. Blood 2009;114:49444953.

    • Search Google Scholar
    • Export Citation
  • 102.

    Hughes T, Saglio G, Branford S. Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase. J Clin Oncol 2009;27:42044210.

    • Search Google Scholar
    • Export Citation
  • 103.

    Khoury HJ, Cortes JE, Kantarjian HM. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. Blood 2012;119:34033412.

    • Search Google Scholar
    • Export Citation
  • 104.

    Hochhaus A, Kim DW, Pinilla-Ibarz J. Molecular responses with ponatinib in patients with philadelphia chromosome positive (ph+) leukemia: results from the PACE trial [abstract]. Blood 2012;120:Abstract 3763.

    • Search Google Scholar
    • Export Citation
  • 105.

    Shah NP, Cortes JE, Kim DW. Impact of baseline (BL) mutations, including low-level and compound mutations, on ponatinib response and end of treatment (EOT) mutation analysis in patients (pts) with chronic phase chronic myeloid leukemia (CP-CML) [abstract]. Blood 2013;122:Abstract 652.

    • Search Google Scholar
    • Export Citation
  • 106.

    Radich J. Stem cell transplant for chronic myeloid leukemia in the imatinib era. Semin Hematol 2010;47:354361.

  • 107.

    Pavlu J, Szydlo RM, Goldman JM, Apperley JF. Three decades of transplantation for chronic myeloid leukemia: what have we learned? Blood 2011;117:755763.

    • Search Google Scholar
    • Export Citation
  • 108.

    Davies SM, DeFor TE, McGlave PB. Equivalent outcomes in patients with chronic myelogenous leukemia after early transplantation of phenotypically matched bone marrow from related or unrelated donors. Am J Med 2001;110:339346.

    • Search Google Scholar
    • Export Citation
  • 109.

    Hansen JA, Gooley TA, Martin PJ. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med 1998;338:962968.

    • Search Google Scholar
    • Export Citation
  • 110.

    Horowitz MM, Rowlings PA, Passweg JR. Allogeneic bone marrow transplantation for CML: a report from the International Bone Marrow Transplant Registry. Bone Marrow Transplant 1996;17(Suppl 3):S56.

    • Search Google Scholar
    • Export Citation
  • 111.

    Crawley C, Szydlo R, Lalancette M. Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. Blood 2005;106:29692976.

    • Search Google Scholar
    • Export Citation
  • 112.

    McSweeney PA, Niederwieser D, Shizuru JA. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001;97:33903400.

    • Search Google Scholar
    • Export Citation
  • 113.

    Or R, Shapira MY, Resnick I. Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase. Blood 2003;101:441445.

    • Search Google Scholar
    • Export Citation
  • 114.

    Faber E, Koza V, Vitek A. Reduced-intensity conditioning for allogeneic stem cell transplantation in patients with chronic myeloid leukemia is associated with better overall survival but inferior disease-free survival when compared with myeloablative conditioning - a retrospective study of the Czech National Hematopoietic Stem Cell Transplantation Registry. Neoplasma 2007;54:443446.

    • Search Google Scholar
    • Export Citation
  • 115.

    Kebriaei P, Detry MA, Giralt S. Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia. Blood 2007;110:34563462.

    • Search Google Scholar
    • Export Citation
  • 116.

    Poire X, Artz A, Larson RA. Allogeneic stem cell transplantation with alemtuzumab-based conditioning for patients with advanced chronic myelogenous leukemia. Leuk Lymphoma 2009;50:8591.

    • Search Google Scholar
    • Export Citation
  • 117.

    Warlick E, Ahn KW, Pedersen TL. Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era. Blood 2012;119:40834090.

    • Search Google Scholar
    • Export Citation
  • 118.

    Weisser M, Schleuning M, Haferlach C. Allogeneic stem-cell transplantation provides excellent results in advanced stage chronic myeloid leukemia with major cytogenetic response to pre-transplant imatinib therapy. Leuk Lymphoma 2007;48:295301.

    • Search Google Scholar
    • Export Citation
  • 119.

    Baccarani M, Cortes J, Pane F. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009;27:60416051.

    • Search Google Scholar
    • Export Citation
  • 120.

    Velev N, Cortes J, Champlin R. Stem cell transplantation for patients with chronic myeloid leukemia resistant to tyrosine kinase inhibitors with BCR-ABL kinase domain mutation T315I. Cancer 2010;116:36313637.

    • Search Google Scholar
    • Export Citation
  • 121.

    Jabbour E, Cortes J, Santos FP. Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations. Blood 2011;117:36413647.

    • Search Google Scholar
    • Export Citation
  • 122.

    Nicolini FE, Basak GW, Soverini S. Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias. Blood 2011;118:56975700.

    • Search Google Scholar
    • Export Citation
  • 123.

    Roth M, Antin J, Ash R. Prognostic significance of Philadelphia chromosome-positive cells detected by the polymerase chain reaction after allogeneic bone marrow transplant for chronic myelogenous leukemia. Blood 1992;79:276282.

    • Search Google Scholar
    • Export Citation
  • 124.

    Delage R, Soiffer R, Dear K, Ritz J. Clinical significance of bcr-abl gene rearrangement detected by polymerase chain reaction after allogeneic bone marrow transplantation in chronic myelogenous leukemia. Blood 1991;78:27592767.

    • Search Google Scholar
    • Export Citation
  • 125.

    Radich JP, Gehly G, Gooley T. Polymerase chain reaction detection of the BCR-ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: results and implications in 346 patients. Blood 1995;85:26322638.

    • Search Google Scholar
    • Export Citation
  • 126.

    Mackinnon S, Barnett L, Heller G. Polymerase chain reaction is highly predictive of relapse in patients following T cell-depleted allogeneic bone marrow transplantation for chronic myeloid leukemia. Bone Marrow Transplant 1996;17:643647.

    • Search Google Scholar
    • Export Citation
  • 127.

    Olavarria E, Kanfer E, Szydlo R. Early detection of BCR-ABL transcripts by quantitative reverse transcriptase-polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood 2001;97:15601565.

    • Search Google Scholar
    • Export Citation
  • 128.

    Radich JP, Gooley T, Bryant E. The significance of bcr-abl molecular detection in chronic myeloid leukemia patients “late,” 18 months or more after transplantation. Blood 2001;98:17011707.

    • Search Google Scholar
    • Export Citation
  • 129.

    Costello RT, Kirk J, Gabert J. Value of PCR analysis for long term survivors after allogeneic bone marrow transplant for chronic myelogenous leukemia: a comparative study. Leuk Lymphoma 1996;20:239243.

    • Search Google Scholar
    • Export Citation
  • 130.

    van Rhee F, Lin F, Cross NC. Detection of residual leukaemia more than 10 years after allogeneic bone marrow transplantation for chronic myelogenous leukaemia. Bone Marrow Transplant 1994;14:609612.

    • Search Google Scholar
    • Export Citation
  • 131.

    Kolb HJ, Schattenberg A, Goldman JM. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995;86:20412050.

    • Search Google Scholar
    • Export Citation
  • 132.

    Dazzi F, Szydlo RM, Cross NC. Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood 2000;96:27122716.

    • Search Google Scholar
    • Export Citation
  • 133.

    Luznik L, Fuchs EJ. Donor lymphocyte infusions to treat hematologic malignancies in relapse after allogeneic blood or marrow transplantation. Cancer Control 2002;9:123137.

    • Search Google Scholar
    • Export Citation
  • 134.

    Michallet AS, Nicolini F, Furst S. Outcome and long-term follow-up of alloreactive donor lymphocyte infusions given for relapse after myeloablative allogeneic hematopoietic stem cell transplantations (HSCT). Bone Marrow Transplant 2005;35:601608.

    • Search Google Scholar
    • Export Citation
  • 135.

    Dazzi F, Szydlo RM, Craddock C. Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia. Blood 2000;95:6771.

    • Search Google Scholar
    • Export Citation
  • 136.

    Shimoni A, Gajewski JA, Donato M. Long-Term follow-up of recipients of CD8-depleted donor lymphocyte infusions for the treatment of chronic myelogenous leukemia relapsing after allogeneic progenitor cell transplantation. Biol Blood Marrow Transplant 2001;7:568575.

    • Search Google Scholar
    • Export Citation
  • 137.

    Gilleece MH, Dazzi F. Donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukaemia. Leuk Lymphoma 2003;44:2328.

    • Search Google Scholar
    • Export Citation
  • 138.

    Posthuma EF, Marijt EW, Barge RM. Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease. Biol Blood Marrow Transplant 2004;10:204212.

    • Search Google Scholar
    • Export Citation
  • 139.

    Simula MP, Marktel S, Fozza C. Response to donor lymphocyte infusions for chronic myeloid leukemia is dose-dependent: the importance of escalating the cell dose to maximize therapeutic efficacy. Leukemia 2007;21:943948.

    • Search Google Scholar
    • Export Citation
  • 140.

    Kantarjian HM, O’Brien S, Cortes JE. Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood 2002;100:15901595.

    • Search Google Scholar
    • Export Citation
  • 141.

    Olavarria E, Ottmann OG, Deininger M. Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Leukemia 2003;17:17071712.

    • Search Google Scholar
    • Export Citation
  • 142.

    Anderlini P, Sheth S, Hicks K. Re: Imatinib mesylate administration in the first 100 days after stem cell transplantation. Biol Blood Marrow Transplant 2004;10:883884.

    • Search Google Scholar
    • Export Citation
  • 143.

    DeAngelo DJ, Hochberg EP, Alyea EP. Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease. Clin Cancer Res 2004;10:50655071.

    • Search Google Scholar
    • Export Citation
  • 144.

    Palandri F, Amabile M, Rosti G. Imatinib therapy for chronic myeloid leukemia patients who relapse after allogeneic stem cell transplantation: a molecular analysis. Bone Marrow Transplant 2007;39:189191.

    • Search Google Scholar
    • Export Citation
  • 145.

    Conchon M, Sanabani SS, Bendit I. The use of imatinib mesylate as a lifesaving treatment of chronic myeloid leukemia relapse after bone marrow transplantation. J Transplant 2009;2009:357093.

    • Search Google Scholar
    • Export Citation
  • 146.

    Hess G, Bunjes D, Siegert W. Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study. J Clin Oncol 2005;23:75837593.

    • Search Google Scholar
    • Export Citation
  • 147.

    Wright MP, Shepherd JD, Barnett MJ. Response to tyrosine kinase inhibitor therapy in patients with chronic myelogenous leukemia relapsing in chronic and advanced phase following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2010;16:639646.

    • Search Google Scholar
    • Export Citation
  • 148.

    Carpenter PA, Snyder DS, Flowers ME. Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia. Blood 2007;109:27912793.

    • Search Google Scholar
    • Export Citation
  • 149.

    Olavarria E, Siddique S, Griffiths MJ. Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia. Blood 2007;110:46144617.

    • Search Google Scholar
    • Export Citation
  • 150.

    Weisser M, Tischer J, Schnittger S. A comparison of donor lymphocyte infusions or imatinib mesylate for patients with chronic myelogenous leukemia who have relapsed after allogeneic stem cell transplantation. Haematologica 2006;91:663666.

    • Search Google Scholar
    • Export Citation
  • 151.

    Savani BN, Montero A, Kurlander R. Imatinib synergizes with donor lymphocyte infusions to achieve rapid molecular remission of CML relapsing after allogeneic stem cell transplantation. Bone Marrow Transplant 2005;36:10091015.

    • Search Google Scholar
    • Export Citation
  • 152.

    Atallah E, Kantarjian H, De Lima M. The role of dasatinib in patients with philadelphia (Ph) positive acute lymphocytic leukemia (ALL) and chronic myeloid leukemia (CML) relapsing after stem cell transplantation (SCT) [abstract]. Blood 2006;108:Abstract 4520.

    • Search Google Scholar
    • Export Citation
  • 153.

    O’Connor LM, Langabeer S, McCann SR, Conneally E. Restoration of donor chimerism by nilotinib in a chronic myeloid leukaemia patient post mutation-associated imatinib mesylate resistance and allogeneic stem cell transplant failure. Bone Marrow Transplant 2008;42:833835.

    • Search Google Scholar
    • Export Citation
  • 154.

    Breccia M, Cannella L, Stefanizzi C. Efficacy of dasatinib in a chronic myeloid leukemia patient with disease molecular relapse and chronic GVHD after haploidentical BMT: an immunomodulatory effect? Bone Marrow Transplant 2009;44:331332.

    • Search Google Scholar
    • Export Citation
  • 155.

    Klyuchnikov E, Schafhausen P, Kroger N. Second-generation tyrosine kinase inhibitors in the post-transplant period in patients with chronic myeloid leukemia or Philadelphia-positive acute lymphoblastic leukemia. Acta Haematol 2009;122:610.

    • Search Google Scholar
    • Export Citation
  • 156.

    Garland P, Dazzi F, Marin D. Dasatinib may not suppress the GVL effect of donor lymphocyte infusions for CML. Bone Marrow Transplant 2010;45:395396.

    • Search Google Scholar
    • Export Citation
  • 157.

    Porkka K, Koskenvesa P, Lundan T. Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. Blood 2008;112:10051012.

    • Search Google Scholar
    • Export Citation
  • 158.

    Ocheni S, Iwanski GB, Schafhausen P. Characterisation of extramedullary relapse in patients with chronic myeloid leukemia in advanced disease after allogeneic stem cell transplantation. Leuk Lymphoma 2009;50:551558.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 446 281 25
PDF Downloads 94 54 10
EPUB Downloads 0 0 0